TheraRadar
← Back
Data updated: Nov 8, 2026

Sarepta Therapeutics

Pharma
ImmunologyDermatology Execution: Fair

Sarepta Therapeutics is a pharmaceutical company focused on Immunology, Dermatology. Key products include ELEVIDYS.

2016
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules 1 Biologics

FDA Novel Drug Designations

(2016-2021)
3 Novel 3 Orphan 3 Accelerated 3 Priority Review 3 Fast Track
See 3 novel approvals →
2021 AMONDYS 45 (CASIMERSEN) Orphan · Priority Review · Accelerated · Fast Track
2019 VYONDYS 53 (GOLODIRSEN) Orphan · Priority Review · Accelerated · Fast Track
2016 EXONDYS 51 (ETEPLIRSEN) Orphan · Priority Review · Accelerated · Fast Track

Sarepta Therapeutics's Key Drugs

Sarepta Therapeutics's core commercial portfolio centers on EXONDYS 51, VYONDYS 53, AMONDYS 45, spanning Immunology and Dermatology — its most strategically important drugs approved in the last 15 years.

EXONDYS 51
Rare Disease

Duchenne Muscular Dystrophy

Dystrophin pre-mRNA Approved 2016
VYONDYS 53
Rare Disease

Duchenne Muscular Dystrophy

Dystrophin pre-mRNA Approved 2019
AMONDYS 45
Rare Disease

Duchenne Muscular Dystrophy

Dystrophin pre-mRNA Approved 2021
ELEVIDYS
DMD Approved 2023

Sarepta Therapeutics's Recent FDA Approvals

New NDA/BLA approvals for Sarepta Therapeutics over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

Sarepta Therapeutics's Therapeutic Areas

Sarepta Therapeutics's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology, across 1 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 95%
0 drugs Phase 3: 7 Phase 2: 7
Dermatology 5%
0 drugs Phase 2: 1

Sarepta Therapeutics's Top Competitors

Sarepta Therapeutics's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Immunology, Dermatology
Eli Lilly big-pharma
Immunology, Dermatology
BAUSCH specialty
Dermatology, Immunology
BAUSCH AND LOMB INC other
Dermatology, Immunology
APOTHECON specialty
Dermatology, Immunology

Sarepta Therapeutics Pipeline Snapshot

Sarepta Therapeutics has 15 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 8 Phase 2 and 0 Phase 1.

7
Phase 3
8
Phase 2
0
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q2 2027
—
Duchenne Muscular Dystrophy
Estimated · stale NCT05881408

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • EXONDYS 51 leads revenue
  • • 4 key drugs tracked

Trial Catalysts

  • • Immunology pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 3/9 completed
  • • Speed: 39 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges